库库比他辛IIa通过增强肠道屏障功能和抑制PERK/ATF4/CHOP信号通路来改善DSS诱导的性结肠炎
1Wuxi No. 2 People's Hospital, Wuxi, China.
概括
库库比他素IIa通过改善肠道屏障功能和减少炎症,有效治疗性结肠炎 (UC). 这种天然化合物向PERK/ATF4/CHOP通路,为UC提供了有前途的治疗方法.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其特点是肠壁功能障碍.
- PERK/ATF4/CHOP信号通路在细胞应激反应和炎症中起着至关重要的作用.
- 识别针对这些途径的新型治疗剂对于UC管理至关重要.
研究的目的:
- 在小鼠模型中研究库库比他辛IIa对硫酸 (DSS) 诱导的性结肠炎的治疗作用.
- 阐明潜在的机制,重点关注肠道屏障完整性和PERK/ATF4/CHOP信号通路.
主要方法:
- 在小鼠中使用3%的DSS诱导UC,然后用库库比他辛IIa进行治疗.
- 评估结肠病理,骨髓氧化酶 (MPO) 活性和炎症性细胞因子水平 (IL-1β,IL-6,TNF-α).
- 分析肠道屏障蛋白 (ZO-1,克劳丁-1,奥克卢丁) 和PERK/ATF4/CHOP通路组件,使用西斑,免疫组织化学,qRT-PCR和免疫光.
主要成果:
- 库库比他辛IIa治疗显著改善了UC小鼠的体重,结肠长度,并降低了UC小鼠的疾病活性指数和MPO活性.
- 经过库库比他辛IIa干预后,组织病理损伤和炎症性细胞因子水平显著降低.
- 库库比他辛IIa抑制了p-PERK,p-eIF2α,ATF4和CHOP的蛋白质表达,同时在mRNA和蛋白质水平上显著上调了ZO-1,Claudin-1和Occludin的表达.
结论:
- 库库比他辛IIa在改善DSS诱导的性结肠炎方面显示出显著的治疗潜力.
- 这些保护作用归因于抑制PERK/ATF4/CHOP信号通路和加强肠道屏障功能.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
2.1K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
378
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
378
01:17Drugs for Treatment of Diarrhea-Predominant IBS
146
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
146
01:29Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110
01:21Inflammatory Bowel Disease V: Surgical Management
116
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
116